Clinical trialNCT06649110RecruitingPhase 1/PHASE2Interventional

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

SponsorNovartis PharmaceuticalsEnrollment232Healthy Volunteers, Pulmonary Arterial Hypertension

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

87 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Novartis Investigative Site
Buenos Aires, Buenos Aires F.D., Argentina
Recruiting
Novartis Investigative Site
CABA, Argentina
Recruiting
Novartis Investigative Site
Río Cuarto, Argentina
Recruiting
Novartis Investigative Site
San Miguel de Tucumán, Argentina
Recruiting
Novartis Investigative Site
Santa Fe, Argentina
Recruiting

Australia

Novartis Investigative Site
Camperdown, New South Wales, Australia
Recruiting
Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Recruiting
Novartis Investigative Site
New Lambton Heights, New South Wales, Australia
Recruiting
Novartis Investigative Site
Adelaide, South Australia, Australia
Recruiting

Belgium

Novartis Investigative Site
Leuven, Vlaams Brabant, Belgium
Recruiting

Brazil

Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Recruiting

Czechia

Novartis Investigative Site
Prague, Czechia
Recruiting
Novartis Investigative Site
Prague, Czechia
Recruiting

France

Novartis Investigative Site
Angers, France, France
Recruiting
Novartis Investigative Site
Brest, France
Recruiting
Novartis Investigative Site
Clamart, France
Recruiting
Novartis Investigative Site
Grenoble, France
Recruiting
Novartis Investigative Site
Montpellier, France
Recruiting
Novartis Investigative Site
Nice, France
Recruiting
Novartis Investigative Site
Pessac, France
Recruiting
Novartis Investigative Site
Poitiers, France
Recruiting
Novartis Investigative Site
Saint-Priest-en-Jarez, France
Recruiting
Novartis Investigative Site
Strasbourg, France
Recruiting
Novartis Investigative Site
Toulouse, France
Recruiting
Novartis Investigative Site
Vandœuvre-lès-Nancy, France
Recruiting

Germany

Novartis Investigative Site
Regensburg, Bavaria, Germany
Recruiting
Novartis Investigative Site
Dresden, Saxony, Germany
Recruiting
Novartis Investigative Site
Berlin, Germany
Recruiting
Novartis Investigative Site
Berlin, Germany
Recruiting
Novartis Investigative Site
Giessen, Germany
Recruiting
Novartis Investigative Site
Greifswald, Germany
Recruiting
Novartis Investigative Site
Heidelberg, Germany
Recruiting
Novartis Investigative Site
Homburg, Germany
Recruiting

Greece

Novartis Investigative Site
Athens, Greece
Recruiting
Novartis Investigative Site
Chaïdári, Greece
Recruiting
Novartis Investigative Site
Thessaloniki, Greece
Recruiting

Italy

Novartis Investigative Site
Foggia, FG, Italy
Recruiting
Novartis Investigative Site
Monza, MB, Italy
Recruiting
Novartis Investigative Site
Palermo, PA, Italy
Recruiting
Novartis Investigative Site
Pavia, PV, Italy
Recruiting

47 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

LTPPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Oct 2024
Primary completion: 29 Nov 2028
Completion: 31 Dec 2028
Last update posted: 21 Jul 2026
Registered enrollment: 232
Registry id: NCT06649110

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.